Numinus Wellness (NUMI.V) finished their first legal extraction of psilocybe mushrooms in Canada for research purposes today, according to a press release.
This follows the company’s completion of their first cultivation and harvest of psilocybe mushrooms at their 7,000 square foot analytics and research laboratory.
“Completing the first legal extraction of Psilocybe mushrooms in Canada is a critical next step to providing a natural product for safe, evidence-based psilocybin-assisted psychotherapies to those in need. Numinus continues to be a vanguard of positive change for the industry, and this announcement demonstrates our ability to deliver yet another first,” said Payton Nyquvest, CEO, founder, and chairman.
Numinus Bioscience is making a good case for themselves as being at the forefront of analytical testing for the emergence of a psychedelic market, as well as as a leading centre for psychedelic product research and development and a potential ancillary for psychedelic therapy clinical trials. They have taken all the necessary steps, including Health Canada licenses, scientific expertise and technologies to facilitate innovation, while generating revenue from high-throughput cannabis testing, which they reinvest into its psychedelics program.
“This is an important milestone in our comprehensive research strategy, following our successful harvest announced in October. In the extraction process, Numinus Bioscience’s goal is to optimize Psilocybe mushrooms to standardize psilocybin and multiple therapeutically important components, increasing the efficacy of the extract. To further our position as a centre of excellence in the space, we are in the process of submitting amendments to supply the extract for use in clinical trials and the Special Access Programme, which, when accepted, will mark a significant move forward in scaling the delivery of psychedelic-assisted therapies,” said Sharan Sidhu, science officer and general manager.
This announcement comes directly preceding Numinus’ advocacy work, which provided contributions to Health Canada’s announcement that it would revise the Special Access Programme (SAP) to extend the provisions common for investigational medications to MDMA and psilocybin-assisted psychotherapy. Also, earlier this week, the company acquired the Montreal-based Mindspace Psychology Services, combining the capabilities of the two Canadian organizations to develop and scale delivery of psychedelic-assisted psychotherapy.
—Joseph Morton
